FGJMX | RYMAX | FGJMX / RYMAX | |
Total Expense Ratio | 0.71 | 1.64 | 43% |
Annual Report Gross Expense Ratio | 0.71 | 1.69 | 42% |
Fund Existence | 7 years | 27 years | - |
Gain YTD | 25.697 | 22.472 | 114% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 0 | 2500 | - |
Min. Initial Investment IRA | N/A | 1000 | - |
Net Assets | 2.26B | 11M | 20,518% |
Annual Yield % from dividends | 0.00 | 0.16 | - |
Returns for 1 year | 41.38 | 31.49 | 131% |
Returns for 3 years | 124.87 | 44.53 | 280% |
Returns for 5 years | 88.49 | 34.95 | 253% |
Returns for 10 years | N/A | 62.03 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
SHPCX | 13.01 | 0.12 | +0.93% |
Saratoga Health & Biotechnology C | |||
NVSCX | 33.10 | 0.06 | +0.18% |
Allspring Small Company Growth Admin | |||
GLCRX | 31.12 | -0.02 | -0.06% |
Goldman Sachs Large Cap Gr Insghts R | |||
OTCNX | 80.12 | -0.18 | -0.22% |
Invesco Discovery Large Cap R | |||
DLQIX | 16.46 | -0.10 | -0.60% |
BNY Mellon Large Cap Equity I |